U.S. Markets closed

Do Balchem Corporation’s (NASDAQ:BCPC) Returns On Capital Employed Make The Cut?

Simply Wall St

Today we are going to look at Balchem Corporation (NASDAQ:BCPC) to see whether it might be an attractive investment prospect. Specifically, we're going to calculate its Return On Capital Employed (ROCE), in the hopes of getting some insight into the business.

First up, we'll look at what ROCE is and how we calculate it. Second, we'll look at its ROCE compared to similar companies. Last but not least, we'll look at what impact its current liabilities have on its ROCE.

Understanding Return On Capital Employed (ROCE)

ROCE is a metric for evaluating how much pre-tax income (in percentage terms) a company earns on the capital invested in its business. All else being equal, a better business will have a higher ROCE. Ultimately, it is a useful but imperfect metric. Author Edwin Whiting says to be careful when comparing the ROCE of different businesses, since 'No two businesses are exactly alike.'

So, How Do We Calculate ROCE?

The formula for calculating the return on capital employed is:

Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities)

Or for Balchem:

0.12 = US$110m ÷ (US$981m - US$82m) (Based on the trailing twelve months to December 2018.)

Therefore, Balchem has an ROCE of 12%.

See our latest analysis for Balchem

Does Balchem Have A Good ROCE?

When making comparisons between similar businesses, investors may find ROCE useful. We can see Balchem's ROCE is around the 12% average reported by the Chemicals industry. Regardless of where Balchem sits next to its industry, its ROCE in absolute terms appears satisfactory, and this company could be worth a closer look.

NasdaqGS:BCPC Past Revenue and Net Income, April 10th 2019

Remember that this metric is backwards looking - it shows what has happened in the past, and does not accurately predict the future. ROCE can be deceptive for cyclical businesses, as returns can look incredible in boom times, and terribly low in downturns. ROCE is only a point-in-time measure. Since the future is so important for investors, you should check out our free report on analyst forecasts for Balchem.

Balchem's Current Liabilities And Their Impact On Its ROCE

Current liabilities are short term bills and invoices that need to be paid in 12 months or less. The ROCE equation subtracts current liabilities from capital employed, so a company with a lot of current liabilities appears to have less capital employed, and a higher ROCE than otherwise. To counteract this, we check if a company has high current liabilities, relative to its total assets.

Balchem has total liabilities of US$82m and total assets of US$981m. Therefore its current liabilities are equivalent to approximately 8.4% of its total assets. Low current liabilities have only a minimal impact on Balchem's ROCE, making its decent returns more credible.

What We Can Learn From Balchem's ROCE

This is good to see, and while better prospects may exist, Balchem seems worth researching further. You might be able to find a better buy than Balchem. If you want a selection of possible winners, check out this free list of interesting companies that trade on a P/E below 20 (but have proven they can grow earnings).

I will like Balchem better if I see some big insider buys. While we wait, check out this free list of growing companies with considerable, recent, insider buying.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.